Research

Hormonal

Tirzepatide 15 mg once weekly produces statistically significant greater reductions in body weight, BMI, and HbA1c compared to semaglutide 2.4 mg once weekly in patients with type 2 diabetes and obesity/overweight.

For patients with type 2 diabetes and obesity, tirzepatide 15mg once weekly is a more effective option for weight loss and blood sugar control than semaglutide 2.4mg. This treatment must be combined with a reduced-calorie diet and regular physical activity. Patients should be aware that while tirzepatide 15mg is more effective, it may have a slightly higher risk of gastrointestinal side effects compared to semaglutide 10mg, though both are generally well-tolerated.

GoodSupportsHIGH confidence
Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide.
Andreea Ciudin et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Based on an indirect treatment comparison (ITC) of two large, robust phase 3 RCTs (SURMOUNT-2 and STEP 2) with similar populations and designs.

Source

Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes

Andreea Ciudin et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16508

Meta-analysis · 2 studiesCited 11×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →